These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27034745)

  • 21. Monthly CERA treatment maintains stable hemoglobin levels in routine clinical practice of peritoneal dialysis patients.
    González MT; Ramos R; Vera M; Barbosa F; Garcia C; Garcia I; González-Segura C; Cuxart M; Teixidó J; José de la Cruz J
    Ren Fail; 2013; 35(3):314-9. PubMed ID: 23356501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum cystatin C level is associated with left atrial enlargement, left ventricular hypertrophy and impaired left ventricular relaxation in patients with stage 2 or 3 chronic kidney disease.
    Sakuragi S; Ichikawa K; Yamada K; Tanimoto M; Miki T; Otsuka H; Yamamoto K; Kawamoto K; Katayama Y; Tanakaya M; Ito H
    Int J Cardiol; 2015; 190():287-92. PubMed ID: 25932809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease.
    Unsal A; Kose Budak S; Koc Y; Basturk T; Sakaci T; Ahbap E; Sinangil A
    Kidney Blood Press Res; 2012; 36(1):55-64. PubMed ID: 22854270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammation, Endothelial Dysfunction and Increased Left Ventricular Mass in Chronic Kidney Disease (CKD) Patients: A Longitudinal Study.
    Ioannou K; Stel VS; Dounousi E; Jager KJ; Papagianni A; Pappas K; Siamopoulos KC; Zoccali C; Tsakiris D
    PLoS One; 2015; 10(9):e0138461. PubMed ID: 26398099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease.
    Fassett RG; Robertson IK; Ball MJ; Geraghty DP; Coombes JS
    Clin Nephrol; 2014 Feb; 81(2):75-85. PubMed ID: 24321183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy.
    Vickery S; Price CP; John RI; Abbas NA; Webb MC; Kempson ME; Lamb EJ
    Am J Kidney Dis; 2005 Oct; 46(4):610-20. PubMed ID: 16183415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients.
    Minutolo R; Zamboli P; Chiodini P; Mascia S; Vitiello S; Stanzione G; Bertino V; Conte G; De Nicola L
    Blood Purif; 2010; 30(3):186-94. PubMed ID: 20924174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T; Sakai Y; Yui S; Sukegawa M; Suzuki A; Mugishima K; Sumi Y; Otsuka Y; Tsuruoka S
    J Nippon Med Sch; 2015; 82(1):21-6. PubMed ID: 25797871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of benefits to non-dialysis CKD patients between darbepoetin alpha and epoetin beta pegol].
    Ito C; Akimoto T; Morishita Y; Yamamoto H; Ogura M; Yamazaki T; Miki A; Homma S; Kusano E; Asano Y; Nagata D
    Nihon Jinzo Gakkai Shi; 2015; 57(7):1233-40. PubMed ID: 26665615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Echocardiography to predict adverse cardiac and vascular events in patients with severe chronic kidney disease (stage 4): a prospective study.
    Lesaffre F; Wynckel A; Nazeyrollas P; Rieu P; Metz D
    Arch Cardiovasc Dis; 2013 Apr; 106(4):220-7. PubMed ID: 23706368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of low-dose Continuous Erythropoietin receptor activator in an experimental model of acute Cyclosporine A induced renal injury.
    Meerwein C; Korom S; Arni S; Inci I; Weder W; Jungraithmayr W
    Eur J Pharmacol; 2011 Dec; 671(1-3):113-9. PubMed ID: 21968143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cardiac markers in different degrees of chronic kidney disease: influence of inflammation and previous heart disease].
    Quiroga B; Goicoechea M; García de Vinuesa S; Verde E; Verdalles U; Yuste C; Reque J; Luño J
    Med Clin (Barc); 2012 Jun; 139(3):98-102. PubMed ID: 21807382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of hemoglobin concentration on plasma B-type natriuretic peptide level and left ventricle echocardiographics characteristics in chronic kidney disease patients.
    Rasić S; Hadzović-Dzuvo A; Tomić M; Uncanin S; Corić S
    Coll Antropol; 2009 Dec; 33 Suppl 2():141-4. PubMed ID: 20120531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monthly continuous erythropoietin receptor activator treatment maintains stable hemoglobin levels in routine clinical management of hemodialysis patients.
    Weinreich T; Leistikow F; Hartmann HG; Vollgraf G; Dellanna F;
    Hemodial Int; 2012 Jan; 16(1):11-9. PubMed ID: 22098689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Left ventricular remodeling and arterial remodeling in patients with chronic kidney disease stage 1-3.
    Pluta A; Stróżecki P; Krintus M; Odrowąż-Sypniewska G; Manitius J
    Ren Fail; 2015 Aug; 37(7):1105-10. PubMed ID: 26156686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Damage of the endothelial glycocalyx in chronic kidney disease.
    Padberg JS; Wiesinger A; di Marco GS; Reuter S; Grabner A; Kentrup D; Lukasz A; Oberleithner H; Pavenstädt H; Brand M; Kümpers P
    Atherosclerosis; 2014 Jun; 234(2):335-43. PubMed ID: 24727235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters.
    Derosa G; Bonaventura A; Bianchi L; Romano D; D'Angelo A; Fogari E; Maffioli P
    J Biol Regul Homeost Agents; 2014; 28(2):317-24. PubMed ID: 25001663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients.
    Washida N; Inoue S; Kasai T; Shinozuka K; Hosoya K; Morimoto K; Wakino S; Hayashi K; Itoh H
    Ther Apher Dial; 2015 Oct; 19(5):450-6. PubMed ID: 25944557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
    Kanbay M; Siriopol D; Saglam M; Kurt YG; Gok M; Cetinkaya H; Karaman M; Unal HU; Oguz Y; Sari S; Eyileten T; Goldsmith D; Vural A; Veisa G; Covic A; Yilmaz MI
    J Clin Endocrinol Metab; 2014 Oct; 99(10):E1854-61. PubMed ID: 25057883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.